Mirum Pharmaceuticals (MIRM) Projected to Post Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM) is projected to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:00 PM ET.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $102.83 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The company’s fifty day moving average price is $87.83 and its 200-day moving average price is $76.82. Mirum Pharmaceuticals has a 1-year low of $36.88 and a 1-year high of $105.74. The firm has a market capitalization of $5.28 billion, a PE ratio of -119.57 and a beta of 0.49.

Insider Activity

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 9,108 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the sale, the chief executive officer owned 160,294 shares in the company, valued at approximately $16,558,370.20. This represents a 5.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jolanda Howe sold 968 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $99,994.40. Following the transaction, the senior vice president owned 4,503 shares in the company, valued at approximately $465,159.90. The trade was a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,136 shares of company stock valued at $4,352,029 in the last three months. Company insiders own 22.87% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at $32,000. Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at approximately $33,000. Quarry LP acquired a new position in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $41,000. Comerica Bank raised its position in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the last quarter. Finally, Osaic Holdings Inc. raised its holdings in Mirum Pharmaceuticals by 46.5% during the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MIRM. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Stifel Nicolaus upped their price target on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Finally, Royal Bank Of Canada set a $130.00 price target on Mirum Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.17.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.